As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ...

With plans to expand its domestic active pharmaceutical ingredient (API) production in the U.S., AbbVie will invest $195 million to build a new manufacturing facility in North Chicago, Illinois. This ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain ...

Lonza completed a laboratory expansion project at its API manufacturing facility in Nansha, China. The project, which grew the footprint of the lab by 250 square meters, included the addition of new ...